SPOTLIGHT: Synthetic Blood touts Phase IIa data

Synthetic Blood International says that a Phase IIa trial of OxyCyte hit its primary endpoint in traumatic brain injury. In line with preliminary study results announced in December 2006, statistical results confirmed that the primary endpoint of increasing patients' oxygen tension levels compared with baseline was met. Release